ライフサイエンスコーパス: explantation

1 implantation, explantation, and 1 year after explantation).

2 l integrity was maintained up to the time of explantation.

3 al mRNAs were detected as early as 9 h after explantation.

4 obtained in culture only with difficulty, by explantation.

5 and cell integration after in vitro retinal explantation.

6 rdial samples taken at LVAD implantation and explantation.

7 d 2.3-fold (P<0.01) and 1.2-fold (P<0.01) at explantation.

8 <0.05) between the times of implantation and explantation.

9 Levels returned to normal by 1 year after explantation.

10 and, in some cases, abundant at the time of explantation.

11 AD placement and subsequently at the time of explantation.

12 ery systems, both improving the ease of lead explantation.

13 of severe vasculopathy at the time of heart explantation.

14 No device thrombosis was observed at explantation.

15 ical aberrations are leading indications for explantation.

16 jection of a selective inhibitor 2 hr before explantation.

17 and its mRNA after axotomy in vivo and after explantation.

18 latory factor-1 (IRF-1) were also induced by explantation.

19 on, could produce a higher incidence of LVAD explantation.

20 e known consequent to an autopsy or surgical explantation.

21 of 28 consecutive patients within 4 hours of explantation.

22 ickness (CCT) were analyzed before and after explantation.

23 d adverse sequelae persisted for years after explantation.

24 Four eyes (2.58%) required IOL explantation.

25 y 3 months postoperatively, prompting device explantation.

26 s, 49.5%) was the most common reason for IOL explantation.

27 omplications following both implantation and explantation.

28 yocardial remission to recovery that allowed explantation.

29 d was an acute rejection, which necessitated explantation.

30 surgery was the most common reason for pIOL explantation.

31 complex procedures such as intraocular lens explantation.

32 n situ for 12 months and for 12 months after explantation.

33 ransport and tested within a few hours after explantation.

34 ft neck and chest 3 months after right-sided explantation.

35 ses, and 1 patient underwent tissue expander explantation.

36 eral HGNS device implantation and subsequent explantation.

37 uggests a 24% probability of successful LVAD explantation.

38 vice replacement and 5 (9%) underwent device explantation.

39 ed from the index TAVR discharge to surgical explantation.

40 and normoglycemia was maintained until graft explantation.

41 eatment in obtaining absence of HCC on liver explantation.

42 e membrane and development of melt requiring explantation.

43 ble improvement can be recognized before VAD explantation.

44 ing the final off-pump trial just before VAD explantation.

45 elationship with cardiac stability after VAD explantation.

46 ith the potential to remain stable after VAD explantation.

47 iteria were the rate of device revisions and explantations.

48 cluding 3 repeat TPV implantations and 2 TPV explantations.

49 In the 11 cases requiring inlay explantations, 100% achieved a corrected distance visual

50 .03%; P = 0.001) leading to a higher rate of explantation (16.4% vs 4.0%; P < 0.001).

51 At explantation, 28 (36%) of 77 patients had HCC, 25 (32%)

52 r weeks; (2) allow reuse of the probes after explantation; (3) be light enough for use in mice.

53 Among patients with KPro explantation, 4 (36.4%) recovered better than baseline v

54 At liver explantation, 57 lesions were present in 18 patients: 19

55 lung explants from six donors (median age at explantation, 71 years [range, 60-83 years]; four men) w

56 levels in mouse trigeminal ganglia following explantation, a stimulus that results in HSV-1 reactivat

57 th a total of 38 lesions who underwent liver explantation after (90)Y radioembolization were studied.

58 istics, predictors, and outcomes of surgical explantation after TAVR using a population-based, nation

59 here is a paucity of information on surgical explantation after transcatheter aortic valve replacemen

60 r implantation and confirmation after sensor explantation allows separation of tissue mass transfer e

61 induction and seed development suggests that explantation and 2,4-D treatment initiates a course of e

62 iod between best cardiac improvement and VAD explantation and also during the final off-pump trial ju

63 adhesive activity recover quickly upon LVAD explantation and are not observed in patients with heart

64 ECD that warrants safe future combined pIOL explantation and cataract surgery.

65 sitive correlation was found between time to explantation and corneal decompensation (r = 0.392, P =

66 Explantation and cutting of articular cartilage activate

67 ine in replicative capacity from the time of explantation and do so in a stochastic manner, with a ha

68 rtance of future mechanistic studies on TAVR explantation and may have implications on lifetime manag

69 specific treatments of the donor heart after explantation and of the recipients.

70 ed with a more proximal cuff, but 3 required explantation and open repair (7%).

71 due to Peyronie's disease, prior prosthesis explantation and priapism, and men who have undergone co

72 We investigated the reasons for pIOL explantation and the associated perioperative complicati

73 an did famciclovir, rates of reactivation by explantation and UV exposure were the same.

74 patients underwent valve intervention (valve explantation and valve-in-valve procedure in 4 and 2 pat

75 ing protocol resulted in a high rate of LVAD explantation and was feasible and reproducible with expl

76 of men in whom the device fails or requires explantation and we present the logical analysis for dev

77 as absence of device extrusion, exchange, or explantation) and functional recovery of 20/200 or bette

78 12 recovery patients (at LVAD implantation, explantation, and 1 year after explantation).

79 t pars plana vitrectomy, subluxated cataract explantation, and FIL SSF IOL implant.

80 istered ethanol (5 g/kg orally) 20 hr before explantation, and grafts were stored in UW cold storage

81 ality, hemodynamic improvement, freedom from explantation, and subjective and objective changes in ex

82 oup developed an infection necessitating DBS explantation, and was excluded from the assessment of th

83 nformed and the contraindications of corneal explantation are clarified.

84 We report the largest series of ICRS explantation as of this writing.

85 lantation, the time between implantation and explantation, as well as IOLs' and patients' characteris

86 Here we use in vivo and explantation assays to investigate tissue interactions a

87 Before explantation, at low flow for 15 minutes, ejection fract

88 One-year survival after LVAD explantation, available in INTERMACS for 21 (11%) patien

89 who underwent Boston type 1 keratoprosthesis explantation because of donor corneal melt at the Illino

90 Explantation because of postoperative subluxation or dis

91 His rate of explantation because of subluxation/dislocation was 0.76

92 various phenotypes whose identification upon explantation can be expensive and time-consuming.

93 All combination pIOL explantation/cataract surgeries resulted in the successf

94 urgical issues and outcomes of combined pIOL explantation/cataract surgery, and the prevention of cat

95 al strategies in performing combination pIOL explantation/cataract surgery.

96 ssues was analyzed by plaque assay, PCR, and explantation cocultivation in both immunocompetent and c

97 y more common in eyes that required a device explantation, compared to those that retained the device

98 PY mRNA also was increased following ganglia explantation, consistent with the increase in the number

99 Among 110 operated eyes, 11 eyes had KPro explantation, corresponding to a failure rate of 0.03/li

100 ng infected porcine corneas for 3 days in an explantation culture system for histologic evaluation of

101 t explantation, reasons for implantation and explantation, date of implantation and explantation, tun

102 At explantation, devices were sonicated and processed for q

103 pIOL explantation due to ECL occurs in eyes with a significan

104 owed relevant instability already before VAD explantation during the time period between best cardiac

105 Explantation/excision is likely to benefit recipients wi

106 Using embryo tissue explantation experiments, we find that the default fate

107 group survived to transplantation and 7% to explantation, findings comparable to those in the Late g

108 valuate outcomes of patients undergoing mesh explantation following partial mesh excision (PME) and c

109 dies have an obligation to facilitate device explantation for participants who request it at study co

110 Independent predictors of device explantation for recovery were age <50 years (odds ratio

111 ollowed prospectively until transplantation, explantation for recovery, death, or for 1 year.

112 Six subjects (9%) underwent LVAD explantation for recovery.

113 omyopathy (4.1%) had highest rates of device explantation for recovery.

114 inally implanted device, transplantation, or explantation for ventricular recovery at 180 days and wa

115 re was a trend of increased mortality in the explantation group (11% versus 8%; P=0.06).

116 rtality risk was slightly higher in the lead explantation group, this difference was not statisticall

117 with implantable cardioverter-defibrillator explantation had an incidence rate of 19.3 (95% confiden

118 g lead abandonment, patients undergoing lead explantation had more in-hospital procedure-related comp

119 Similarly, patients undergoing lead explantation had slightly higher rates of in-hospital de

120 ed a higher mortality in those with surgical explantation (hazard ratio: 4.03 vs. no-explant group; 9

121 quired multiple surgical interventions after explantation, highlighting the long-term morbidity assoc

122 lavien in 22%, and required premature device explantation in 16%.

123 The management included IOL explantation in 7 of 9 cases, removal of fibrosis with p

124 r chamber modifications, and recommends PIOL explantation in cases of an increase in the crystalline

125 inhibition and pRb dephosphorylation on MEF explantation in culture.

126 clinical recovery is insufficient for device explantation in most patients with chronic heart failure

127 rative evaluation for both groups and before explantation in the E group and 8 years post-implantatio

128 ly week 4 was chosen as the optimum time for explantation in the in vivo assay in that sufficient cal

129 ore 1:1 matching for ICD lead abandonment or explantation in the National Cardiovascular Data Registr

130 s not associated with increased risk of mesh explantation in the setting of enterectomy.

131 by retinal detachment in vivo and in retinal explantation in vitro.

132 sal tissue extirpation and cardiac primordia explantation indicate that cardiac left-right orientatio

133 al activity and relatively high frequency of explantation-induced reactivation in both immunocompeten

134 Rates of explantation, infection, tissue necrosis, and hematoma w

135 bility after ventricular assist device (VAD) explantation is a major goal.

136 Boston KPro explantation is a serious complication.

137 entricular assist device implantation and at explantation (mean duration, 185+/-156 days) and from 9

138 ent fracture, or corrosion up to the time of explantation (median, 119 days; first and third quartile

139 On the day of ECMO explantation (median, postoperative day 8), LV diameter

140 On explantation (n = 3276), 13% had microvascular invasion,

141 patients who had RAP > or = 15 mm Hg at LVAD explantation (n = 8) or who required an RV assist device

142 h debridement; however, no instances of mesh explantation occurred.

143 , with a survival rate to transplantation or explantation of 78%.

144 [SD], 68 [11] year; 65% male) who underwent explantation of a knee or hip prosthesis due to suspecte

145 incidence, timing, and outcomes of surgical explantation of a TAVR prosthesis.

146 orylation of MAP kinase that usually follows explantation of explants.

147 V failures) experienced persistent hypotony, explantation of implant, or loss of light perception com

148 Explantation of infarcted neonatal and adult heart tissu

149 who experienced long-term survival after an explantation of infected VADs and OHT.

150 imulation.RESULTSImplantation and subsequent explantation of intracortical microelectrodes were carri

151 oteins were activated for up to 8 days after explantation of SCG in vitro.

152 2011, the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly un

153 l of immunosuppression, graft rejection, and explantation of the allograft after rejection has been e

154 Hyperglycemic blood glucose levels after explantation of the capsules confirmed the function of t

155 After explantation of the capsules, all mice became hyperglyce

156 ) were rapidly activated upon dissection and explantation of the cartilage.

157 Explantation of the decentered/dislocated IOL along with

158 e studied; 6 recovered sufficiently to allow explantation of the device compared with 9 who did not r

159 in all subjects except in one, who required explantation of the device without further complications

160 er sufficient ventricular function to enable explantation of the device.

161 cardial function, sufficient enough to allow explantation of the device.

162 sistance can lead to myocardial recovery and explantation of the device.

163 Repositioning or explantation of the implant occurred in 6.8% of MicroShu

164 repositioning of the flexible electrodes and explantation of the interface after chronic implantation

165 e of fewer severe complications that lead to explantation of the intraocular lens.

166 cant decrease in visual quality and possibly explantation of the IOL.

167 cardiomyocytes obtained from tissue taken at explantation of the LVAD in patients with clinical recov

168 t, 214 days) at the time of implantation and explantation of the LVAD.

169 Explantation of the LVADs without heart transplantation

170 Explantation of the pIOL occurred in 6.0% in the myopic

171 ed intravitreal antibiotics in all patients, explantation of the XEN stent in 5 patients (62.5%), and

172 patients who recovered sufficiently to allow explantation of their LVAD can even achieve cardiac and

173 feasible, some may have to undergo surgical explantation of their transcatheter heart valve (TAVR-ex

174 te from latency in vivo after DEX treatment, explantation of tonsil tissue from calves latently infec

175 Surgical explantation of transcatheter heart valves (THVs) is rap

176 ular route, and virus was not recovered upon explantation of trigeminal ganglia; (iv) although protei

177 observed in 76 to 82% of the eyes following explantation onto a permissive cell layer.

178 clinical outcomes after an intraocular lens explantation or exchange have also improved markedly wit

179 accompany the study of viral reactivation by explantation or peripheral viral shedding.

180 were either already infected at the time of explantation or soon after through cell-to-cell contact

181 btained through postmortem versus antemortem explantation or whether explantation was due to infectio

182 Large-scale studies to better address post-explantation outcomes are warranted.

183 ry were a better last-recorded vision before explantation (P = .0002) and better vision immediately a

184 actinin decreased by 1.6-fold at the time of explantation (P<0.05).

185 were reviewed for patient demographics, pre-explantation parameters, complications, management, and

186 D implantation (pre-LVAD) and at the time of explantation (post-LVAD).

187 egral component failure that required device explantation prior to reaching elective replacement.

188 he grasp, pull, and refold technique for IOL explantation provides a simpler surgery, less complicati

189 nts who retain the device, but a significant explantation rate due to infection or local complication

190 ICRSs (119 patients) were explanted, with an explantation rate of 5.60%.

191 The secondary outcome was mesh explantation rates for emergent open repairs performed w

192 Mesh explantation rates up to 10 years after surgery were not

193 linical data included age of the patients at explantation, reasons for implantation and explantation,

194 IGF-I mRNA was elevated at the time of LVAD explantation relative to donors, with 2 groups distingui

195 Histology of the thymic grafts at explantation revealed viable thymus with preservation of

196 Histology of the thymic autografts at explantation revealed viable thymus with preservation of

197 Microarray analysis of implantation and explantation samples of recovery patients further reveal

198 ever, some patients with LVEF >45 before VAD explantation show early recurrence of heart failure (HF)

199 rather than sequential, lung-abdominal organ explantation strategy for DCD donation to prioritize liv

200 Explantation studies provided evidence that myocardial c

201 ted the increase of STAT binding produced by explantation, suggesting the presence of a labile repres

202 antation were not associated with worse post-explantation survival (all p > 0.05).

203 After explantation survival free from LVAD or transplantation

204 ve and less invasive alternative to surgical explantation (TAVR-explant) to treat transcatheter heart

205 (ii) After explantation the amounts of viral mRNAs increased wherea

206 Main outcome measures were the reason for explantation, the time between implantation and explanta

207 In 68% of all explantations, the surgical course was unremarkable, whi

208 led description of the methodology for heart explantation, tissue preparation, slicing with a vibrato

209 l samples were collected at implantation and explantation/transplantation.

210 n and explantation, date of implantation and explantation, tunnel creation technique, and ICRS type.

211 Device explantation utilized closure devices alone in 61%, sten

212 After explantation, ventricular function declined in 2 PPCM pa

213 Final visual prognosis correlates with pre-explantation visual function (r = 0.68, P = .02).

214 The incidence of surgical explantation was 0.2% (227 of 132,633 patients), and was

215 The mean time for explantation was 12.58 +/- 3.79 years for the E group.

216 The mean follow-up after explantation was 35.5 38.1 months.

217 Median time to explantation was 45.5 months (range: 6.0-140.1 months).

218 he mean time between primary surgery and IOL explantation was 57.0 +/- 38.9 months.

219 Five-year freedom from reintervention and explantation was 76+/-4% and 92+/-3%, respectively.

220 In 24 cases, the reason for IOL explantation was a centrally localized opacification, th

221 em versus antemortem explantation or whether explantation was due to infection or upgrade.

222 The main cause of explantation was functional refractive failure followed

223 MyoRing explantation was performed in 4 eyes (4%).

224 ent bleedings; and in 1 case artificial iris explantation was performed owing to chronic inflammation

225 Case data including the reason for explantation was taken from the patient records.

226 is and subsequent surgery that required pIOL explantation was the reason in 42% of all cases.

227 The time between implantation and explantation was the shortest in cases with intraoperati

228 up, time and causes of device replacement or explantation were assessed and categorized.

229 ts with KPro retention, those requiring KPro explantation were associated with aniridia (P = .0038),

230 Patients with KPro explantation were identified and compared to those with

231 The most frequent reasons for early IOL explantation were IOL dislocation (32%), visual intolera

232 Indications for early IOL explantation were IOL dislocation, visual intolerance, o

233 ose mRNA level was modified by the stress of explantation were isolated and sequenced.

234 Eyes that underwent IOL exchange or explantation were nearly two and a half times more likel

235 me-to-surgical-explant, and year of surgical explantation were not associated with worse post-explant

236 A total of 53 lungs removed at autopsy or explantation were obtained for the study from 51 documen

237 If ICD generator explantations were performed instead of replacements in

238 No FAi explantations were required, nor were any participants l

239 Patients were aged 76.31 +/- 8.24 years at explantation, which was performed 81.5 +/- 32.2 months a

240 Eyes with AC IOL explantation with glued IOL implantation in a single set

241 combination with endothelial damage prompted explantation, with 26, 18 and 14% for G1, G2 and G3 resp

242 of myocardial function to reach criteria for explantation within 18 months with sustained remission f

243 s, whereas 8.8% and 70.9% underwent surgical explantation within 30 days and 1 year, respectively.

244 nalyze the causes and characteristics of IOL explantation within the first year after primary implant

245 implant retention (DAIR) in 34 (18.2%), and explantation without reimplantation in 7 (3.7%) patients

246 ents are sufficient to allow ultimate device explantation without requiring transplantation; this rep